Our strategic approach is about advancing science to benefit patients most in need of new therapies. As a private company led ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

IDH-mutant gliomas have changes in the IDH1 or IDH2 gene. These genes instruct your body to produce isocitrate dehydrogenase (IDH) enzymes, which help release energy for cells to use.

Shortly after the discovery of the molecular underpinnings of IDH mutations, several programs were initiated to develop drugs to inhibit the neomorphic enzymatic function of mIDH, and thus block ...

Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a “breakthrough,” whereas others call the approval “premature.” ...

Researchers have revealed how IDH mutations in gliomas act as a "ticking time bomb," initiating slow growth before genetic mutations drive aggressive cancer progression. The study highlights ...

Patients with grade 2 astrocytoma or oligodendroglioma should be selected for treatment based on the presence of IDH1 or IDH2 mutations in tumor specimens. Voranigo ® is supplied as a tablet in 2 ...

In addition to this newly FDA-approved drug, the IDH gene discovery led to a new classification of gliomas, differentiating cancers with an IDH mutation that have overall better outcome and response ...

The FDA on Tuesday signed off on Servier Pharmaceuticals ’ oral treatment vorasidenib for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene. The drug will be marketed ...

The new FDA approval is for Servier’s Voranigo, or vorasidenib, for adult and children ages 12 and older with low-grade glioma with a susceptible IDH1 or IDH2 mutation.

FDA Approves First Targeted Therapy for Gliomas With IDH Mutations. Sharon Worcester, MA. August 06, 2024 . 0.